Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Confident in the Future of Bria-IMT Following its Demonstrated Success in Clinical Trials

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 12:46pm EDT

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, sees a promising future for its lead product candidate, Bria-IMT. An article discussing the company reads, “The company recently presented promising results for two of its clinical studies (monotherapy and combination study of Bria-IMT with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]) for patients with advanced breast cancer during the 2018 San Antonio Breast Cancer Symposium in Texas (http://nnw.fm/5YriX).  … ‘I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,’ Dr. Bill Williams, BriaCell’s president & CEO, said of the company’s presentation at the international symposium that attracted over 7,000 academic and private physicians and researchers (http://nnw.fm/Po3A0).  ‘These findings also reinforce our product development strategy for Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.’”

To view the full article, visit http://nnw.fm/Tm2FS

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Copyright © 2015 - 2019 NetworkNewsWire, source NetworkNewsWire

Stocks mentioned in the article
ChangeLast1st jan.
BRIACELL THERAPEUTICS CORP -6.25% 0.075 Delayed Quote.0.00%
MERCK AND COMPANY 1.54% 80.96 Delayed Quote.4.35%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
03:55a2019 Anti-infective Drugs Market | North America To Witness Long-Term Growth ..
AQ
07/11WALL STREET STOCK EXCHANGE : S&P 500, Dow climb as health insurers, financials g..
RE
07/11Merck on Pace for Largest Percent Decrease Since October 2017 -- Data Talk
DJ
07/11VIDEO REPORT : Aytu BioScience (NASDAQ: AYTU) Heats Up The Summer With Natesto a..
AQ
07/10MERCK AND : FDA Accepts Merck's Supplemental Biologics License Applications for ..
AQ
07/10MERCK : Highlights Commitment to HIV Research with Presentations for Investigati..
BU
07/09Health Care Up as Trump's Drug-Price Disclosure Rule Blocked - Health Care Ro..
DJ
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/09MERCK AND : Sees FDA OK for Six-Week Keytruda Dosing in Six Indications
DJ
07/09MERCK AND : FDA Accepts Merck's Supplemental Biologics License Applications for ..
BU
More news
Financials (USD)
Sales 2019 44 662 M
EBIT 2019 15 107 M
Net income 2019 10 015 M
Debt 2019 18 019 M
Yield 2019 2,74%
P/E ratio 2019 20,1x
P/E ratio 2020 16,4x
EV / Sales2019 5,07x
EV / Sales2020 4,73x
Capitalization 208 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 92,1  $
Last Close Price 81,0  $
Spread / Highest target 19,8%
Spread / Average Target 13,8%
Spread / Lowest Target 4,99%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY4.35%208 546
JOHNSON & JOHNSON4.07%372 000
PFIZER-2.86%238 617
ROCHE HOLDING LTD.7.93%233 930
ROCHE HOLDING9.69%233 930
NOVARTIS17.29%206 941